DK3091029T5 - Anti-IL13-antistofformuleringer - Google Patents

Anti-IL13-antistofformuleringer Download PDF

Info

Publication number
DK3091029T5
DK3091029T5 DK16169916.0T DK16169916T DK3091029T5 DK 3091029 T5 DK3091029 T5 DK 3091029T5 DK 16169916 T DK16169916 T DK 16169916T DK 3091029 T5 DK3091029 T5 DK 3091029T5
Authority
DK
Denmark
Prior art keywords
antibody formulations
antibody
formulations
Prior art date
Application number
DK16169916.0T
Other languages
English (en)
Other versions
DK3091029T3 (da
Inventor
Ajay Deshmukh
Joumana Zeid
Thomas M Scherer
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of DK3091029T3 publication Critical patent/DK3091029T3/da
Publication of DK3091029T5 publication Critical patent/DK3091029T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
    • A61M5/178—Syringes
    • A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or cartridges, e.g. automatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Materials For Medical Uses (AREA)
DK16169916.0T 2011-10-31 2012-10-30 Anti-IL13-antistofformuleringer DK3091029T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553916P 2011-10-31 2011-10-31
EP12846324.7A EP2773662A4 (en) 2011-10-31 2012-10-30 ANTIBODY FORMULATIONS

Publications (2)

Publication Number Publication Date
DK3091029T3 DK3091029T3 (da) 2023-01-30
DK3091029T5 true DK3091029T5 (da) 2024-10-14

Family

ID=48192677

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16169916.0T DK3091029T5 (da) 2011-10-31 2012-10-30 Anti-IL13-antistofformuleringer

Country Status (27)

Country Link
US (4) US10000562B2 (da)
EP (3) EP4218937A3 (da)
JP (4) JP6120452B2 (da)
KR (4) KR102259829B1 (da)
CN (5) CN109078182B (da)
AR (2) AR088579A1 (da)
AU (3) AU2012332767C1 (da)
BR (1) BR112014008864B1 (da)
CA (2) CA2849210C (da)
DK (1) DK3091029T5 (da)
ES (1) ES2936387T3 (da)
FI (1) FI3091029T3 (da)
HK (1) HK1201857A1 (da)
HR (1) HRP20230153T1 (da)
HU (1) HUE061728T2 (da)
IL (2) IL232053B (da)
LT (1) LT3091029T (da)
MX (2) MX363226B (da)
MY (2) MY187874A (da)
PL (1) PL3091029T3 (da)
PT (1) PT3091029T (da)
RS (1) RS63948B1 (da)
RU (1) RU2665810C2 (da)
SG (1) SG11201401903PA (da)
SI (1) SI3091029T1 (da)
WO (1) WO2013066866A1 (da)
ZA (2) ZA201401779B (da)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2857499A1 (en) 2010-10-01 2015-04-08 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CN103702646B (zh) 2011-06-24 2016-03-30 凯希特许有限公司 采用组织固定元件的减压敷件
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PT3682905T (pt) 2011-10-03 2022-04-07 Modernatx Inc Nucleósidos, nucleótidos e ácidos nucleicos modificados e respetivas utilizações
EP2771031B1 (en) 2011-10-28 2018-04-18 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
AU2012332767C1 (en) * 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations
ES2923757T3 (es) 2011-12-16 2022-09-30 Modernatx Inc Composiciones de ARNm modificado
EP2807188B1 (en) 2012-01-27 2019-09-11 Prothena Biosciences Limited Humanized antibodies that recognize alpha-synuclein
WO2013151664A1 (en) 2012-04-02 2013-10-10 modeRNA Therapeutics Modified polynucleotides for the production of proteins
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
PT2922554T (pt) 2012-11-26 2022-06-28 Modernatx Inc Arn modificado nas porções terminais
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
SG11201601823TA (en) 2013-09-13 2016-04-28 Genentech Inc Methods and compositions comprising purified recombinant polypeptides
PL3044323T3 (pl) 2013-09-13 2022-06-27 F.Hoffmann-La Roche Ag Sposoby wykrywania i ilościowego oznaczania białka komórki gospodarza w liniach komórkowych
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
KR20160067219A (ko) 2013-10-03 2016-06-13 모더나 세라퓨틱스, 인코포레이티드 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드
WO2015079977A1 (ja) * 2013-11-26 2015-06-04 シャープ株式会社 抗体分離方法、抗体評価方法、医薬の評価方法、及び、抗体の２次元電気泳動用キット
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
MX380066B (es) 2014-12-23 2025-03-11 Merz Pharma Gmbh & Co Kgaa Recipiente precargado con toxina botulinica.
ES3053874T3 (en) * 2015-08-24 2026-01-27 Glaxosmithkline Ip No 2 Ltd Biopharmaceutical compositions
WO2017189805A1 (en) 2016-04-27 2017-11-02 Abbvie Inc. Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
US11464810B2 (en) * 2016-08-25 2022-10-11 California Institute Of Technology Ascaroside treatment of eosinophilic esophagitis
TWI787203B (zh) 2016-09-23 2022-12-21 美商建南德克公司 Il-13拮抗劑用於治療異位性皮炎之用途
US10980881B2 (en) * 2017-01-11 2021-04-20 Celltrion Inc. Stable liquid formula having an anti-TNFalpha antibody, acetate buffer and glycine
JP2019048091A (ja) * 2018-10-23 2019-03-28 ニプロ株式会社 デクスメデトミジン注射液を充填したプレフィルドシリンジ
AU2019333836B2 (en) * 2019-01-02 2023-11-09 Tosoh Corporation Light scattering detectors and methods for the same
US12643950B1 (en) * 2019-02-07 2026-06-02 Takeda Pharmaceutical Company Limited Autoinjector comprising high concentration formulation of vedolizumab
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP4065166A4 (en) * 2019-11-26 2023-12-20 Comera Life Sciences, Inc. EXCIPIENT COMPOUNDS FOR BIOPOLYMER FORMULATIONS
AU2021365008A1 (en) * 2020-10-22 2023-06-08 Allakos Inc. Anti-siglec-8 antibody formulations
TWI847170B (zh) 2021-07-16 2024-07-01 美商德米拉股份有限公司 用於治療異位性皮炎之il-13抗體
TWI859566B (zh) 2021-08-13 2024-10-21 美商德米拉股份有限公司 用於治療異位性皮膚炎之il-13抗體
IL311027A (en) * 2021-09-15 2024-04-01 Dermira Inc Il-13 inhibitors for the treatment of prurigo nodularis
IL316779A (en) 2022-05-05 2025-01-01 Dermira Inc IL-13 antibodies for the treatment of atopic dermatitis
KR20250025381A (ko) 2022-06-17 2025-02-21 아포지 바이오로직스, 인크. 인터류킨 13에 결합하는 항체 및 사용 방법
KR20250154502A (ko) 2023-03-08 2025-10-28 더미라, 인코포레이티드 아토피성 피부염의 치료를 위한 il-13 항체
EP4788430A1 (en) 2023-10-05 2026-08-12 Ashibio, Inc. Methods and compositions for treating mmp-9 mediated disorders
CN122374333A (zh) 2023-12-14 2026-07-10 德米拉公司 用于治疗慢性鼻窦炎伴鼻息肉的il-13抗体
AU2024399620A1 (en) 2023-12-14 2026-05-14 Dermira, Inc. Il-13 antibodies for the treatment of perennial allergic rhinitis
IL328386A (en) * 2023-12-20 2026-07-01 Apogee Therapeutics Inc Pharmaceutical formulations of antibodies that bind interleukin 13
AU2024406222A1 (en) 2023-12-20 2026-06-04 Bristol-Myers Squibb Company Antibodies targeting il-18 receptor beta (il-18rβ) and related methods
CN122396699A (zh) * 2023-12-20 2026-07-14 顶峰疗法股份有限公司 具有和不具有c末端赖氨酸的抗il-13抗体的药物组合物
WO2025155802A1 (en) * 2024-01-19 2025-07-24 Allakos Inc. Anti-siglec-6 antibody formulations
TW202600591A (zh) 2024-03-01 2026-01-01 美商德米拉股份有限公司 用於治療發炎後皮膚色素過多或色素過少之ｉｌ—１３抗體
WO2026076260A1 (en) 2024-10-03 2026-04-09 Ashibio, Inc. Methods and compositions for mmp-9 inhibition for use with non-genetic heterotopic ossification disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4925673A (en) 1986-08-18 1990-05-15 Clinical Technologies Associates, Inc. Delivery systems for pharmacological agents encapsulated with proteinoids
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
JPH08503950A (ja) 1992-12-02 1996-04-30 アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド 徐放性成長ホルモン含有マイクロスフェア
EP1002529A1 (en) 1994-09-09 2000-05-24 Takeda Chemical Industries, Ltd. Sustained-release preparation containing a metal salt of a peptide
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
SK281571B6 (sk) 1995-06-07 2001-05-10 Alkermes Controlled Therapeutics, Inc. Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
KR100797667B1 (ko) 1999-10-04 2008-01-23 메디카고 인코포레이티드 외래 유전자의 전사를 조절하는 방법
US7288390B2 (en) 2000-08-07 2007-10-30 Centocor, Inc. Anti-dual integrin antibodies, compositions, methods and uses
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
JP4533626B2 (ja) * 2001-11-07 2010-09-01 サイトス バイオテクノロジー アーゲー アレルギー性好酸球性疾患を治療するための抗原アレイ
US7425618B2 (en) 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EA009079B1 (ru) * 2003-02-28 2007-10-26 Арес Трейдинг С.А. Жидкие составы фактор некроза опухоли-связывающих белков
PT1610820E (pt) 2003-04-04 2010-12-16 Novartis Ag Formulações de elevada concentração de anticorpos e proteínas
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
MX361174B (es) * 2003-12-23 2018-11-29 Genentech Inc Anticuerpos anti-il13 novedosos y sus usos.
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR101363777B1 (ko) 2005-09-30 2014-02-14 메디뮨 리미티드 인터루킨―１３ 항체 조성물
EP2532677A1 (en) * 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
TWI395754B (zh) * 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
JP5419709B2 (ja) * 2007-01-09 2014-02-19 ワイス・エルエルシー 抗ｉｌ−１３抗体製剤およびその使用
CA2676881C (en) * 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
NZ592970A (en) * 2008-12-03 2013-05-31 Astellas Deutschland Gmbh Oral dosage forms of bendamustine
PE20120359A1 (es) * 2009-03-06 2012-04-13 Genentech Inc Formulacion con anticuerpo
SI3409289T1 (sl) 2010-02-26 2020-12-31 Novo Nordisk A/S Stabilni sestavki, ki vsebujejo protitelo
KR101878369B1 (ko) * 2010-03-22 2018-07-16 제넨테크, 인크. 단백질-함유 제제의 안정화에 유용한 조성물 및 방법
BR112012027828A2 (pt) 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2012332767C1 (en) 2011-10-31 2017-02-02 Genentech, Inc. Antibody formulations

Also Published As

Publication number Publication date
LT3091029T (lt) 2023-02-27
CN109078182A (zh) 2018-12-25
CN121910869A (zh) 2026-04-24
US10000562B2 (en) 2018-06-19
AU2012332767B2 (en) 2016-05-12
MY187874A (en) 2021-10-26
RU2014116070A (ru) 2015-12-10
IL276234B (en) 2022-04-01
EP2773662A1 (en) 2014-09-10
MX363226B (es) 2019-03-15
ES2936387T3 (es) 2023-03-16
US10947307B2 (en) 2021-03-16
AU2018232943A1 (en) 2018-10-11
HUE061728T2 (hu) 2023-08-28
US20140348855A1 (en) 2014-11-27
RU2665810C2 (ru) 2018-09-04
MX2019002979A (es) 2020-02-10
AR124140A2 (es) 2023-02-15
JP2014532664A (ja) 2014-12-08
EP4218937A2 (en) 2023-08-02
US20260055178A1 (en) 2026-02-26
KR102259829B1 (ko) 2021-06-03
ZA201401779B (en) 2019-07-31
CA2849210A1 (en) 2013-05-10
JP2016193922A (ja) 2016-11-17
AU2012332767C1 (en) 2017-02-02
NZ622654A (en) 2017-01-27
IL232053A0 (en) 2014-05-28
JP2019203002A (ja) 2019-11-28
PL3091029T3 (pl) 2023-04-11
JP6120452B2 (ja) 2017-04-26
PT3091029T (pt) 2023-02-03
SI3091029T1 (sl) 2023-03-31
IL232053B (en) 2020-08-31
JP6921148B2 (ja) 2021-08-18
BR112014008864A2 (pt) 2018-08-07
KR101994809B1 (ko) 2019-07-01
BR112014008864B1 (pt) 2021-11-09
US12492247B2 (en) 2025-12-09
KR20140084078A (ko) 2014-07-04
JP2018048166A (ja) 2018-03-29
CN108704132A (zh) 2018-10-26
AU2018232943B2 (en) 2020-07-23
MX2014004992A (es) 2014-08-27
WO2013066866A1 (en) 2013-05-10
CA2849210C (en) 2020-07-14
FI3091029T3 (fi) 2023-03-20
DK3091029T3 (da) 2023-01-30
CN104039826A (zh) 2014-09-10
AU2016210757A1 (en) 2016-08-25
HRP20230153T1 (hr) 2023-03-31
HK1201857A1 (en) 2015-09-11
US20190002552A1 (en) 2019-01-03
CN109078182B (zh) 2022-08-12
CA3078979A1 (en) 2013-05-10
EP2773662A4 (en) 2015-07-01
IL276234A (en) 2020-09-30
CN116077644A (zh) 2023-05-09
AU2012332767A1 (en) 2014-04-10
MY197851A (en) 2023-07-20
US20210155684A1 (en) 2021-05-27
KR20200065104A (ko) 2020-06-08
CA3078979C (en) 2022-10-11
RS63948B1 (sr) 2023-02-28
SG11201401903PA (en) 2014-05-29
ZA201901490B (en) 2021-06-30
KR20170096212A (ko) 2017-08-23
KR20190077127A (ko) 2019-07-02
JP6272950B2 (ja) 2018-01-31
EP4218937A3 (en) 2023-10-25
AR088579A1 (es) 2014-06-18
EP3091029B1 (en) 2022-12-28
EP3091029A1 (en) 2016-11-09

Similar Documents

Publication Publication Date Title
DK3091029T3 (da) Anti-IL13-antistofformuleringer
DK3117837T3 (da) Antistofformuleringer
CO6801637A2 (es) Formulaciones de anticuerpos
DK3620175T3 (da) Højkoncentrerede antistofformuleringer
HRP20211423T4 (hr) Formulacije enzalutamida
PT2720563T (pt) Resumo
EP2782540A4 (en) CHAIR WITH ROLLERS
DK2694038T3 (da) Farmaceutisk sammensætning
BR112014002399A2 (pt) conjunto
EP2747556A4 (en) pyrethroid formulations
EP2673344A4 (en) STABLE BIO OIL
PT2543357T (pt) Resumo
HRP20160887T1 (hr) Formulacije testosterona
CO6940426A2 (es) Formulaciones farmacéuticas
CO6761402A2 (es) Formulaciones inmunosupresoras
BR112014000015A2 (pt) formulação
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
HRP20171889T1 (hr) Formulacije kombinacije darunavira
BR112014005756A2 (pt) vacina
PT2661870T (pt) Resumo
EP2769718A4 (en) MEDICAL COMPOSITION
EP2742058C0 (en) ANTI-IL-6 VACCINE COMPOSITION
IL231660A0 (en) Composition
EP2770828A4 (en) FORMULATION
IL228573A0 (en) Otamixaban formulations with improved stability